Ignite Creation Date:
2024-05-05 @ 4:35 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00264849
Status:
COMPLETED
Last Update Posted:
2018-06-29
First Post:
2005-12-12
Brief Title:
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Open Label Parallel-group International Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Who Remain Inadequately Controlled Despite GINA 2004 Step 4 Therapy
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma who demonstrate inadequate asthma symptom control Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma
THIS STUDY IS NOT ENROLLING PATIENTS IN THE US
THIS STUDY IS NOT ENROLLING PATIENTS IN THE US
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None